A Multi-center, Randomized, Double-blind, Parallel Controlled Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Anti RANKL Monoclonal Antibody Injection (MW032) and Denosumab (Xgeva®) in Subjects With Bone Metastases From Solid Tumors
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases
- Focus Registrational; Therapeutic Use
- Sponsors Mabwell (Shanghai) Bioscience
- 08 Apr 2024 According to a Mabwell Therapeutics Media Release, T-mab has officially obtained the marketing authorization approval by National Medical Products Administration (NMPA) (Drug Approval Number: [GYZZ]S20240010). MAIWEIJIAN is the denosumab biosimilar (120mg) approved for marketing in China.
- 21 Feb 2024 According to a Mabwell Therapeutics Media Release, results from this study were published in journal of JAMA Oncology.
- 21 Feb 2024 Results presented in a Mabwell Therapeutics Media Release